Additional Resources and Assistance

CareASSIST is here to help you get the information and support you need. In addition to the program offerings, you may also find the following downloads and online resources helpful.

CareASSIST Downloads

CareASSIST Application Download

CareASSIST Application

The CareASSIST application covers all aspects of the program: Access and Reimbursement, Financial Assistance, and Resource Support. Follow the directions on the form to apply, or call 1-833-WE+CARE (1-833-930-2273) to get started.

CareASSIST Brochure Download

CareASSIST Brochure

The CareASSIST brochure contains an overview of the program and its offerings.

CareASSIST Copay Program Overview Brochure Download

CareASSIST Copay Program Overview Brochure

The CareASSIST Copay Program overview brochure describes the program and its requirements.

CareASSIST Resource Navigation Flashcard Download

CareASSIST Resource Navigation Flashcard

An overview of potential sources of prescription assistance.

Online Resources

Certain patients may require information or assistance beyond what CareASSIST may offer. Below are links to external organizations that may be able to help, or you can call 1-833-WE+CARE (1-833-930-2273) to learn about alternate coverage options.

Medicaid.gov

Learn about Medicaid in your state and if you may be eligible.

Medicare.gov

Learn about Medicare and prescription drug coverage, eligibility, and how to access the care you may need.

Patient Advocate Foundation

Find help for insurance and healthcare access problems.

Patient Access Network Foundation

Offers help and hope to people with chronic or life-threatening illnesses for whom cost limits access to breakthrough medical treatments.

American Cancer Society

A nationwide, community-based voluntary health organization dedicated to eliminating cancer as a major health problem.

Cancer Support Community

A global network offering quality cancer support to millions of people touched by cancer, available online and at community-based centers and hospitals.

National Comprehensive Cancer Network®

A not-for-profit alliance of 28 leading cancer centers devoted to patient care, research, and education.

CancerCare

A leading national organization dedicated to providing free support services and financial assistance to anyone affected by cancer.

INDICATION

ELITEK is indicated for the initial management of plasma uric acid levels in patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anticancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid. ELITEK is indicated only for a single course of treatment.

IMPORTANT SAFETY INFORMATION

WARNING: HYPERSENSITIVITY REACTIONS, HEMOLYSIS, METHEMOGLOBINEMIA, AND INTERFERENCE WITH URIC ACID MEASUREMENTS

  • Hypersensitivity Reactions: ELITEK can cause serious and fatal hypersensitivity reactions including anaphylaxis. Immediately and permanently discontinue ELITEK in patients who experience a serious hypersensitivity reaction.
  • Hemolysis: Do not administer ELITEK to patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Immediately and permanently discontinue ELITEK in patients developing hemolysis. Screen patients at higher risk for G6PD deficiency (e.g., patients of African or Mediterranean ancestry) prior to starting ELITEK.
  • Methemoglobinemia: ELITEK can result in methemoglobinemia in some patients. Immediately and permanently discontinue ELITEK in patients developing methemoglobinemia.
  • Interference with Uric Acid Measurements: ELITEK enzymatically degrades uric acid in blood samples left at room temperature. Collect blood samples in pre-chilled tubes containing heparin and immediately immerse and maintain sample in an ice water bath. Assay plasma samples within 4 hours of collection.

CONTRAINDICATIONS
ELITEK is contraindicated in patients with a history of anaphylaxis or severe hypersensitivity to rasburicase or in patients with development of hemolytic reactions or methemoglobinemia with rasburicase. ELITEK is contraindicated in individuals deficient in glucose-6-phosphate dehydrogenase (G6PD).

ADVERSE REACTIONS
Most common adverse reactions (incidence ≥20%), when used concomitantly with anticancer therapy, are vomiting, nausea, fever, peripheral edema, anxiety, headache, abdominal pain, constipation, diarrhea, hypophosphatemia, pharyngolaryngeal pain, and increased alanine aminotransferase.

USE IN SPECIFIC POPULATIONS

  • Pregnancy: Consider the benefits and risks of ELITEK and possible risks to the fetus when prescribing ELITEK to a pregnant woman.
  • Lactation: Because of the potential for serious adverse reactions in the breastfed child, advise patients that breastfeeding is not recommended during treatment with ELITEK and for 2 weeks after the last dose.